US2007099253A1PendingUtilityA1
Method for producing a specific antiserum against the universal tumorous antigen and method for diagnosing malignant tumours using said antiserum
Est. expiryApr 20, 2018(expired)· nominal 20-yr term from priority
A61P 35/00G01N 33/575C07K 16/30A61K 39/395
30
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention pertains to the field of medicine and may be used for producing a specific antiserum as well as for carrying out immunological diagnoses of malignant tumours. This method for producing an antiserum involves sampling an embryo at the foetal stage from animals of a same genetic type so as to obtain a cell suspension. After immunization, spleen cells from the animal are sampled, lymphocytes are separated and an animal of the same genetic line is immunized with the lymphocyte suspension. Cells originating from healthy organs of the same animals are added to the obtained antiserum. The serum is then purified away from the sediments. In order to carry out a diagnosis, the filtrate is added to the subject's blood and the results are obtained by an immunodetection method. It is thus possible to diagnose a tumour when the test values obtained differ from reference values.
Claims
exact text as granted — not AI-modified1 . A method for producing an anti-idiotypic antiembryonic antiserum that specifically binds antigen-stimulated lymphocytes, comprising:
i) performing a first immunization by immunizing an animal with a suspension of cells of tissue of a fetus of the same genetic line as the animal that is immunized; ii) recovering spleen cells from said immunized animal and separating lymphocytes therefrom, thus obtaining a lymphocyte suspension; iii) performing a second immunization by immunizing an animal of the same genetic line as the animal that is first immunized with said lymphocyte suspension; iv) recovering an antiserum from said animal immunized in the second immunization; v) adding cells of whole organs of kidney, lung and liver of a normal animal of the same genetic line as the immunized animal to said antiserum, forming a suspension; and vi) separating the supernatant from the sediments from the obtained suspension to obtain the anti-idiotypic antiembryonic antiserum that specifically binds antigen-stimulated lymphocytes.
2 . The method according to claim 1 , in which the separation of the supernatant from the sediments is carried out by filtration.
3 . The method of claim 1 , in which the second immunization is performed as repeated administrations of the cell suspension over an interval of time.
4 . A method for, diagnosis of a malignant tumor comprising:
i) performing a sample test by a) contacting an antiserum obtained by the method of claim 1 with a sample of a tissue, blood or other physiologic sample of a human subject to be examined, and b) detecting binding of antibodies of the antiserum to the sample; and ii) determining the presence of a malignant tumor by deviation of the test result from a control test.
5 . A method for diagnosis of a malignant tumor comprising:
i) performing a sample test by a) contacting an antiserum obtained by the method of claim 2 with a sample of a tissue, blood or other physiologic sample of a human subject to be examined, and b) detecting binding of antibodies of the antiserum to the sample; and ii) determining the presence of a malignant tumor by deviation of the test result from a control test.
6 . A method for diagnosis of a malignant tumor comprising:
i) performing a sample test by a) contacting an antiserum obtained by the method of claim 3 with a sample of a tissue, blood or other physiologic sample of a human subject to be examined, and b) detecting binding of antibodies of the antiserum to the sample; and ii) determining the presence of a malignant tumor by deviation of the test result from a control test.
7 . The method according to claim 4 , in which the method of immunodetection is an immuno-fluorescence test or an erythrocyte sedimentation test.
8 . The method according to claim 5 , in which the method of immunodetection is an immuno-fluorescence test or an erythrocyte sedimentation test.
9 . The method according to claim 6 , in which the method of immunodetection is an immuno-fluorescence test or an erythrocyte sedimentation test.
10 . The method according to claim 4 , in which an erythrocyte sedimentation test is used and a diagnosis of the presence of a malignant tumor is made when α is greater than or equal to 1.5 and
α
=
(
A
-
B
1
+
B
2
2
)
×
X
50
wherein:
A is the index of the ESR of sample test,
B 1 and B 2 are indices of the ESR of tests upon control samples,
X is the maximum value of the ESR observed in the test.
11 . The method according to claim 5 , in which an erythrocyte sedimentation test is used and a diagnosis of the presence of a malignant tumor is made when α is greater than or equal to 1.5 and
α
=
(
A
-
B
1
+
B
2
2
)
×
X
50
wherein:
A is the index of the ESR of sample test,
B 1 and B 2 are indices of the ESR of tests upon control samples,
X is the maximum value of the ESR observed in the test.
12 . The method according to claim 5 , in which an erytlrocyte sedimentation test is used and a diagnosis of the presence of a malignant tumor is made when α is greater than or equal to 1.5 and
α
=
(
A
-
B
1
+
B
2
2
)
×
X
50
wherein:
A is the index of the ESR of sample test,
B 1 and B 2 are indices of the ESR of tests upon control samples,
X is the maximum value of the ESR observed in the test.
13 . An antiserum obtained by the method of claim 1 .
14 . An antiserum that specifically binds to an antigen present in embryonic cells and in malignant tumors and that specifically binds to a receptor of a T-cell that is specifically reactive with a malignant tumor cell.Join the waitlist — get patent alerts
Track US2007099253A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.